ArticleAnnals of thoracic surgery short reports2026
Valved Femoral Vein Homografts as Right Ventricle to Pulmonary Artery Conduit for Repair of Truncus Arteriosus.
Article in Annals of thoracic surgery short reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To assess outcomes of early surgical repair of truncus arteriosus by analyzing outcomes with the use of valved femoral vein homografts as right ventricle to pulmonary artery conduit. Methods: Between 2002 and 2023, 51 patients who underwent primary surgical repair for truncus arteriosus were reviewed retrospectively. Results: Median (interquartile range) age and weight were 7 (5.7-17.5) days and 3 (2.6-3.7) kg. Median follow-up was 7 (3-17) years. Survival was 86% and 81% at 1 and 15 years, respectively. Birth weight below 2 kg, conduit size of 10 mm or smaller, and the need for extracorporeal membrane oxygenation were associated with higher mortality. Valved femoral vein homografts were utilized in 29 (57%, 29 of 51) patients, pulmonary artery homografts in 11 (22%, 11 of 51), aortic homografts in 7 (14%, 7 of 51), valveless tube grafts in 3 (6%, 3 of 51), and a bioconduit in 1 (2%, 1 of 51). Thirty (59%, 30 of 51) patients underwent conduit replacement within a median of 2.7 (1.7-4.8) years. No difference was observed among conduit types based on the time from truncus arteriosus repair to conduit reintervention or replacement ( Conclusions: Valved femoral vein homografts are durable as right ventricle to pulmonary artery conduits in early primary repair of truncus arteriosus. The choice of appropriately sized conduit reduces the rate of reintervention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.